Back to top
more

Tempus AI, Inc. (TEM)

(Delayed Data from NSDQ)

$54.89 USD

54.89
6,563,419

-1.70 (-3.00%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $54.90 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

by Urmimala Biswas

TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.

Zacks Equity Research

The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk

by Zacks Equity Research

TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.

Sridatri Sarkar headshot

Tempus AI Taps Growing ICI Market With New xM Assay

by Sridatri Sarkar

TEM launches xM, a liquid biopsy assay to monitor real-time response to ICI therapy in advanced solid tumors.

Urmimala Biswas headshot

Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?

by Urmimala Biswas

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

Sridatri Sarkar headshot

Tempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum

by Sridatri Sarkar

TEM secures FDA clearance for its AI-powered ECG tool targeting heart failure, as AI ECG adoption accelerates.

Urmimala Biswas headshot

TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?

by Urmimala Biswas

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Sridatri Sarkar headshot

Tempus AI Raises 2025 Financial Outlook: What's Backing It?

by Sridatri Sarkar

TEM lifts its 2025 revenue and EBITDA outlook on strong Q1 results, key partnerships and testing expansion.

Sridatri Sarkar headshot

Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches

by Sridatri Sarkar

TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.

Urmimala Biswas headshot

Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release

by Urmimala Biswas

TEM's revenue and gross profit are climbing fast as new AI tools and data services boost margins ahead of Q2 earnings.

Zacks Equity Research

Hims & Hers Enhances Healthcare Through AI-Driven Personalization

by Zacks Equity Research

HIMS taps AI and $870 million in funding to deliver smarter, more personalized healthcare through tech-driven innovation.

Sridatri Sarkar headshot

What's Fueling Tempus AI's Explosive Sales Growth?

by Sridatri Sarkar

TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.

Moumi Mondal headshot

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?

by Moumi Mondal

TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.

Urmimala Biswas headshot

TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?

by Urmimala Biswas

GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.

Moumi Mondal headshot

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

by Moumi Mondal

TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.

Moumi Mondal headshot

Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach

by Moumi Mondal

TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.

Urmimala Biswas headshot

Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?

by Urmimala Biswas

Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?

Moumi Mondal headshot

Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?

by Moumi Mondal

TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Tempus AI, SoundHound AI and Innodata

by Zacks Equity Research

Tempus AI, SoundHound AI, and Innodata post surging growth, offering overlooked exposure to the booming AI trend.

Derek Lewis headshot

3 AI Stocks Flying Under the Radar

by Derek Lewis

Outside of the big-time AI players, several companies with notable AI exposure, including Tempus AI, SoundHound AI, and Innodata, have been seemingly overlooked by many.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Nvidia, Alphabet, Constellation Energy and Meta Platform

by Zacks Equity Research

Nvidia surges amid AI boom as Propense.ai and Tempus AI push into law and healthcare with game-changing tech.

Andrew Rocco headshot

Beyond LLMs: How Propense.ai & Tempus AI are Shaking up Legacy Industries

by Andrew Rocco

While large language models have been the primary focus of Wall Street, the real asymmetric returns for savvy growth investors will likely come from lesser-known AI segments disrupting legacy industries. Firms like Propense.ai, with its AI-powered B2B cross-selling platform, are gaining traction.

Urmimala Biswas headshot

Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?

by Urmimala Biswas

BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Palantir, Tempus AI and Comfort Systems USA

by Zacks Equity Research

Palantir, Tempus AI and Comfort Systems USA are part of the Zacks Investment Ideas article.

Derek Lewis headshot

These 3 AI-Related Stocks Crushed Earnings

by Derek Lewis

We continue to wade through the 2025 Q1 cycle, which has been notably positive for these three companies with AI exposure. How long will the theme persist?

Urmimala Biswas headshot

After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?

by Urmimala Biswas

President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.